Headline: Incyte (INCY) Secures Japan Approval for Minjuvi in DLBCL Treatment

Incyte (INCY) announced on June 19, 2026, that its drug Minjuvi (tafasitamab) received approval in Japan for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplantation. This regulatory milestone expands the drug's global market presence. Minjuvi, developed in partnership with MorphoSys AG, is marketed as Monjuvi in the U.S., where it received accelerated approval in 2020. The European Commission also granted conditional marketing authorization for the drug in 2021. DLBCL is recognized as the most prevalent type of non-Hodgkin lymphoma. The Japanese approval specifies Minjuvi's use in combination with lenalidomide, followed by Minjuvi monotherapy.